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Abstract
Background: Associations between a pro-inflammatory state and schizophrenia have been one of the more
enduring findings of psychiatry, with various lines of evidence suggesting a compelling role for IL-6 in the
underlying pathogenesis of schizophrenia.
Methods: In this study, we examined IL-6 mRNA levels by real-time RT-PCR from fresh extracted peripheral blood
mononuclear cells (PBMC) in normal controls and participants with schizophrenia.
Results: We found that peripheral PBMC IL-6 mRNA levels, in the absence of any other information, reliably
discriminated between a diagnosis of schizophrenia and normal controls. Furthermore, in participants with
schizophrenia, we also found elevated levels of IL-6 mRNA with earlier ages of illness onset and worse positive
symptom presentation, as measured by the Positive and Negative Syndrome Scale.
Conclusions: These findings provide important and continued support for a pathophysiological role of
inflammation in patients with schizophrenia. Future utilization of peripheral IL-6 mRNA levels could be clinically
useful during an initial diagnosis and help tailor individualized treatment plans for patients with schizophrenia.
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Background
Patients with schizophrenia have altered immune func-
tion [1]. This, coupled with studies indicating the impact
of maternal illness on offspring development [2, 3],
strongly suggests a link between the inflammasome and
schizophrenia. As such, interleukin 6 (IL-6), which can
function as both a pro- and anti-inflammatory cytokine-
has been examined for its role in the development,
course, symptomology, and applicability as a biomarker
of schizophrenia.
Various lines of evidence suggest a compelling role for
IL-6 in the underlying pathogenesis of schizophrenia.
First and foremost, IL-6 and sIL-6R serum levels are sig-
nificantly elevated in patients with schizophrenia [4, 5],
with implications for symptom severity [6]. The single-
nucleotide polymorphism (SNP) G/C at position -174 of
the IL-6 gene may also result in increased susceptibility
to schizophrenia, although this seems to be highly
dependent on environmental factors [7]. This SNP has
also been linked to overall symptomology in schizophre-
nia [8, 9]. Maternal immune activation models of neuro-
developmental insults have heralded insight into the role
of IL-6 and schizophrenia. Maternally produced cyto-
kines can both cross the placenta [10] and induce an
acute-phase reaction in response to immune challenges
[11]. A single maternal dose of IL-6 results in
schizophrenic-like behavioral changes in rodent off-
spring [12]. Furthermore, inhibiting IL-6 action in re-
sponse to an immune challenge can normalize these
behaviors in adult offspring [12]. Thus, multiple lines of
evidence link inflammatory factors, specifically IL-6,
with mental illness and related symptomology.
In this study, we demonstrate that IL-6 mRNA levels
from freshly extracted peripheral blood mononuclear
cells (PBMC) could be a useful and easily clinically ac-
cessible biomarker for a diagnosis of schizophrenia.
There is a general lack of correlation between cytokine
serum levels and PBMC gene expression [13]. As such,
measurement of mRNA in PBMC is tissue specific and
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avoids interpretation regarding the source of serum
levels of cytokines, which could emanate from the liver,
muscle, adipose and other tissues. Additionally, we
attempted to elucidate the role of IL-6 in disease onset
and symptom presentation in schizophrenia.
Methods
Participants
The sample included 106 participants, including 53 pa-
tients with schizophrenia and 53 healthy individuals re-
cruited from the University of Illinois at Chicago (UIC)
medical center and surrounding community. All study
procedures were approved by The Office for the Protec-
tion of Research Subjects at UIC. All participants pro-
vided written informed consent before participating in
any study procedures. Patients with schizophrenia were
assessed by experienced diagnosticians (MD or PhD) via
Structured Clinical Interview for DSM Disorders (SCID)
interview, DSM-IV-TR criteria and all available informa-
tion. Clinicians established a consensus before final as-
signment to diagnostic group. All participants were
between 21-65 years of age and in good physical health
(with no reported infections or autoimmune diseases),
and exclusion criteria were: a history of neurological dis-
ease or head trauma, lifetime history of substance/alco-
hol dependence or recent substance abuse, and
pregnancy for women. Exclusionary criteria for control
participants also included a major Axis I disorder
(assessed by a SCID interview) and a known first-degree
familial history of psychosis. Participant demographics
are listed on Table 1.
At the time of sampling, 55 % (n = 29) of the patients
with schizophrenia were evaluated while hospitalized
on the inpatient psychiatric unit and 45 % (n = 24) were
evaluated in the psychiatric outpatient clinic. Pre-
scribed antipsychotic medication was coded on all par-
ticipants as follows: Haloperidol = 2, Fluphenazine = 2,
Perphenazine = 2, Risperidone = 19, Olanzapine = 3,
Quetiapine = 7, Ziprasidone = 3, Aripiprazole = 4,
Lurasidone = 3, Iloperidone = 1, Paliperidone = 2, (a total
of n = 48). Five patients were unmedicated at the time of
the blood draw. Due to this heterogeneity, all anti-
psychotic use was converted to Chlorpromazine (CPZ)
units [14, 15].
Clinical measures
From all patients with schizophrenia, age of symptom
onset was collected. Additionally, the Positive and
Negative Syndrome Scale (PANSS) was administered to
all clinical participants. The PANSS is used to generate
measures of positive, negative, and general psychopath-
ology through using a 7-point scale, with ratings ran-
ging from 1 (symptom is absent) to 7 (symptom is
extreme) [16].
Peripheral blood mononuclear cell extraction
A blood sample was obtained by sterile venipuncture
into a 0.5 M EDTA anticoagulant filled tube. Peripheral
blood mononuclear cells (PBMC) were extracted utiliz-
ing the Ficoll-Paque® method (GE Healthcare Life Sci-
ences) [17]. Subsequent washing of the cream-colored
interlayer was performed using the Hanks Balanced Salt
Solution (HBSS – Gibco #14170-161) to remove any
remaining platelets, plasma or other contaminants.
PBMC samples were pelleted at 2,000RPM for ten mi-
nutes at 10 °C and frozen in TRIzol reagent -80 °C until
mRNA extraction.
mRNA extraction and quantitative real-time RT-PCR
Total RNA was isolated using TRIzol reagent (Life Tech-
nologies) and treated with DNase (Ambion/Life Tech-
nologies AM1906) after extraction. Only total RNA
extracts with an OD260/OD280 ratio above 1.96, indi-
cating relatively pure RNA, were processed for RT-PCR,
the remainder undergoing re-extraction using the stand-
ard phenol-chloroform extraction protocol. Total RNA
was used to prepare cDNA via the Applied Biosystems
High Capacity cDNA Reverse Transcription Kit
(#4368814). For detection and measurement of expres-
sion, Fermentas Maxima SYBR Green/ROX qPCR Mas-
ter Mix (#K0222) was used. PCR mixtures were run on a
Thermo Scientific PikoReal real-time PCR System using
the following conditions: 95 °C for 10 min, followed by
40 cycles of 95 °C for 30 s, 60 °C for one minute and
72 °C for one minute. Cycle threshold (CT) value was
Table 1 Means and standard deviations of participant
demographics comparing healthy controls and participants with
schizophrenia in PBMC samples
Demographic Healthy Controls Patients with
Schizophrenia
Sex (M/F) 24/29 34/19
t = 1.97; p = 0.052
Age (Mean ± SD) 35.5 ± 11.4 36.8 ± 11.8
t = -0.57; p = 0.57
Race (%)
Caucasian, non-Hispanic 17 (32) 4 (8)
Black, non-Hispanic 18 (34) 39 (73)
Asian or other Pacific Islander 11 (21) 3 (6)
Hispanic 7 (13) 7 (13)
F(1,105) = 0.10; p = 0.75
BMI (Mean ± SD) 29.3 ± 8.5 31.6 ± 7.7
t = -1.36; p = 0.18
Waist Circumference 39.8 ± 8.45 42.0 ± 8.17
t = -1.26; p = 0.209
Statistical differences between the various parameters were determined by a
Student’s t-test or one way ANOVA, with results indicated
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used for relative quantification, and all values were nor-
malized to three housekeeping genes, GAPDH, TFRC
and β-Actin (chosen for their previously, unpublished
determined stability across diagnostic groups) using a
geometric mean, and run in triplicate [18–20]. Primer
sequences are listed in Table 2.
Statistical analysis
SPSS (version 15.0 for Windows) was used for all statis-
tical analyses. Analysis of all mRNA data was conducted
on CT levels of the gene of interest, normalized to the
geometric mean of three control genes. Data is pre-
sented as mean values ± standard error. A probability
level of p < 0.05 was the criterion to achieve statistical
significance.
Results
Shapiro Wilk analysis for normality
Normality of IL-6 mRNA distributions in both diagnos-
tic groups was assessed by Shapiro-Wilk W tests where
a p < 0.05 rejects the null hypothesis that the distribution
is normal. Results indicate that the distribution for both
controls and participants with schizophrenia was not
normal, p = 0.001 and p = 0.008 respectively. Thus, for
all further data analysis we utilized non-parametric tests,
including the Mann-Whitney U, Spearman correlations,
two-sample Kolmogorov-Smirnov test and the Receiver
Operating Characteristic.
Comparison of IL-6 mRNA expression levels in PBMC
We performed a Mann-Whitney U analysis with PBMC
IL-6 mRNA as the dependent variable and diagnosis as
the independent variable. We discovered that partici-
pants with a diagnosis of schizophrenia had significantly
higher IL-6 mRNA levels when compared to normal
controls (U = 632.5, p < 0.001). There were no significant
differences between diagnosis and measurements of sex,
age, race, BMI or waist circumference, as determined by
either a Student’s t-test or a One Way Analysis of Vari-
ance (ANOVA; Table 1). The mean value of IL-6 mRNA
levels for control participants is 3.11 ± 1.7 (standard de-
viation). The mean value for PBMC IL-6 mRNA levels
in participants with schizophrenia is 5.64 ± 3.0 (Fig. 1).
IL-6 mRNA correlates with clinical scales
We found that higher PBMC IL-6 mRNA levels were as-
sociated with earlier onset of psychiatric symptoms
(PBMC IL-6 mRNA x age of symptom onset; Spearman’s
ρ = –0.23, p = 0.02; Fig. 2a). We also found that increases
in IL-6 mRNA levels were correlated with increased
presentation of positive symptoms, as measured by the
PANSS (Spearman’s ρ = 0.35, p = 0.014; Fig. 2b).
Two-sample Kolmogorov-Smirnov test
A two-sample Kolmogorov-Smirnov (KS) test was used
to compare the distributions of IL-6 mRNA levels be-
tween controls and participants with schizophrenia [21].
The KS test was significant (p < 0.001), supporting the
hypothesis that the two samples originate from different
distributions (Fig. 3).
Receiver operating characteristic analysis
A receiver operating characteristics (ROC) curve was
generated to examine the diagnostic value of using IL-6
mRNA as a binary classifier (patient with schizophrenia
vs. controls). For this analysis, the area under the ROC
curve (AUC) represents the predictive value of using
only PBMC IL-6 mRNA levels to accurately differentiate
between participants with schizophrenia and healthy
controls across all of IL-6 mRNA levels found in our
sample. While an AUC of 0.50 indicates there is no diag-
nostic value of IL-6 mRNA, an AUC greater than 0.50
indicates a greater than chance probability of success-
fully discriminating diagnoses from a randomly chosen
sample of the IL-6 mRNA data. Notably, the AUC of IL-
6 from PBMC was 0.76, with a 95 % confidence interval
of 0.66-0.85 (p < 0.001; Fig. 4). This result demonstrates
that IL-6 mRNA levels can reliably discriminate between
a diagnosis of schizophrenia from normal controls in
our sample (~25 % better than chance).
Table 2 Real-time RT-PCR mRNA primers utilized for this study
Primer
Name






Fig. 1 IL-6 mRNA levels in peripheral blood mononuclear cells (PBMC).
IL-6 mRNA levels were significantly increased in participants with
schizophrenia when compared to normal controls. Data presented as
mean and SEM, p < 0.05
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Discussion
Our results demonstrate that IL-6 mRNA levels from
freshly extracted PBMC are significantly upregulated in
participants with schizophrenia when compared to
healthy controls, thereby confirming our hypothesis. We
also demonstrate that IL-6 mRNA levels are significantly
elevated in patients who had an earlier age of onset, as
well as those who demonstrated worse positive symp-
tomatology. Finally, IL-6 levels may be a useful bio-
marker for a diagnosis of schizophrenia due to the
predictive capabilities we demonstrate here.
Associations between a pro-inflammatory state and
schizophrenia have been one of the more enduring find-
ings of the field [4]. Our finding of an elevation in levels
Fig. 2 Clinical correlates with IL-6 mRNA levels (a) IL-6 mRNA levels were increased in participants with an earlier age of illness onset. b IL-6
mRNA levels were higher in participants with increased positive symptom presentation, as measured by the Positive and Negative Syndrome
Scale (PANSS). Spearman rho values, sample size and significance levels are all listed on individual graphs
Fig. 3 Distributions of IL-6 mRNA levels between controls and participants with schizophrenia. The two-sample Kolmogorov-Smirnov test is
significant (p < 0.001), demonstrating that the two diagnostic groups originate from different distributions
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of IL-6 is consistent with the majority of the literature
[6, 9, 22, 23]. One such study, by Frydecka, et al., [23]
found that serum IL-6 levels were significantly higher in
participants with schizophrenia when compared to
healthy controls. Additionally, in their sample, elevated
IL-6 serum levels were associated with longer duration
of illness. Our study complements and extends these
findings. Importantly, IL-6 levels examined in this
manuscript are mRNA from peripheral blood mono-
nuclear cells. IL-6 levels measured in the serum, as in
the Frydecka paper, can originate from multiple tissues,
including adipose, muscle and liver, with particularly
confounding effects given the well known metabolic dis-
turbances in the schizophrenia population [24, 25]. Thus
the demonstrated elevated serum IL-6 levels could have
originated at any number of locations, thereby making
the true source, cause, and implications difficult to inter-
pret. Additionally, the Frydecka et al., study found no as-
sociations between symptom presentation, as measured
by the PANSS, and serum IL-6 levels, while we found a
correlation with IL-6 mRNA levels and positive symp-
toms [23]. These differences may be attributable to the
differences in type of biochemical sample examined be-
tween our two studies, paving the way for further discus-
sion as to the importance of the location of the IL-6
signal and its role in mental illness.
Due to the heterogeneity of prescribed psychotropic
medication in our naturalistic study, all antipsychotic
use was converted to Chlorpromazine (CPZ) units. The
impact of psychotropic medication on the inflamma-
some in participants with schizophrenia is a dynamic
and novel field. Levels of proinflammatory cytokines are
significantly elevated in female patients treated with clo-
zapine, when compared to healthy controls [26]. How-
ever, these participants had significantly increased BMI
levels when compared to normal controls, a phenotype
associated with elevated cytokine levels, further compli-
cating the interpretation. Additionally, treatment with
olanzapine for 8 weeks reduces plasma IL-2 levels, but
results in no changes in IL-6 or TNFa levels [27]. Treat-
ment with chlorpromazine inhibits TNFa, but upregu-
lates peripheral IL-10 levels in mice [28]. These findings
all indicate that more research is needed regarding the
uncontrollable variable of psychotropic medications play
in the larger picture of inflammation and schizophrenia.
The association between IL-6 mRNA levels with age of
onset and positive symptomatology is consistent with
previous literature. In schizophrenia, serum IL-6 levels
are positively correlated with PANSS Scores [29], an as-
sociation our data replicates and extends on by examin-
ing this correlation with PBMCs. In schizophrenia, age
of illness onset is a crucial determinant of clinical out-
comes [30, 31], with a younger onset-age correlated with
a worse disease prognosis and increased symptom pres-
entation [32–34]. IL-6 levels are associated with younger
psychosis onset, longer duration of illness and worse ill-
ness presentation [23], all indicators of worse disease
course. IL-6 has been proposed to act as a “state marker”
for schizophrenia, with elevated serum levels seen in
first episode psychosis and acutely relapsed patients [35].
These listed studies are all in line with our findings that
the underlying pathophysiology of schizophrenia is char-
acterized by a low-grade inflammatory state. It is import-
ant to the field to present multiple lines of consistent
data regarding elevated levels of IL-6 in participants with
schizophrenia in independent cohorts. Additionally, fur-
ther studies need to be conducted examining IL-6
mRNA levels in participants with schizophrenia when
compared to other psychiatric disorders, specifically
depression.
Previous work has explored the use of IL-6 as a clin-
ical predictor, but for infection in febrile neutropenia
[36], not schizophrenia. In schizophrenia research, the
receiver operating characteristic analysis has been used
to examine the predictive value of specific microRNAs
not associated with the immune system [37, 38]. Our
work merges these two concepts to examine the predict-
ive value of PBMC IL-6 mRNA levels in schizophrenia.
Interestingly, evidence indicates that IL-6 levels are in-
creased in schizophrenia-risk subjects, with highest
levels demonstrated in those who transitioned from risk
to acute psychosis [39]. This suggests that IL-6 could
serve as a pre-diagnostic tool for identifying individuals
who are more likely to suffer from the disease. In the
clinic, an especially useful aspect of the ROC is criterion;
a cutoff that attempts to maximize the likelihood of a
true positive (accurate diagnosis) while minimizing the
chance of an incorrect diagnosis (false positive). In our
data set, using a cutoff IL-6 mRNA value of 4.9
Fig. 4 A receiver operating characteristics (ROC) curve analysis of
the diagnostic value of IL-6 mRNA from primary blood mononuclear
cells (PBMC). An area under the curve (AUC) value of 0.76 indicates
the predictive capability of IL-6 mRNA levels for a diagnosis of
schizophrenia in our sample
Chase et al. BMC Psychiatry  (2016) 16:152 Page 5 of 7
(arbitrary units) would result in a true positive rate of
53 %, while a false positive would occur 17 % of the
time. If the cutoff value is increased, the chance of a true
positive increases, while false positives decrease. For ex-
ample, a cutoff of 6.0 in our sample would be five times
more likely to make a correct diagnosis of schizophrenia
based solely on IL-6 mRNA levels in PBMC. In the
clinic, physicians would have access to much more pa-
tient data, and thus could adjust their criterion as
needed to ensure an accurate diagnoses.
Conclusions
Accessible biological markers are desperately needed to
improve the timing and accuracy of a diagnosis of
schizophrenia. These findings provide important support
for a pathophysiological role for inflammation in pa-
tients with schizophrenia. While not strong enough to
stand as a predictor of schizophrenia on its own, IL-6
mRNA levels may be yet another tool for clinicians to
use during either an initial diagnosis or for tailoring in-
dividualized treatment plans for patients with schizo-
phrenia. The application of accurate in vitro diagnostic
tools that can accurately classify psychiatric disorders or
identify disease subtypes could help to reduce illness
duration and cost, including hospital services and loss of
work, and improve treatment outcomes. Although such
personalized medicine is still expensive, with the lighten-
ing speed of new technological development, these costs
are rapidly decreasing [40]. In conclusion, although fur-
ther studies using a larger cohort of participants are
needed, data from the present study suggest that periph-
eral blood mononuclear cell level of IL-6 mRNA has diag-
nostic relevancy and predictive value in schizophrenia.
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